TSHA
Price
$2.54
Change
-$0.11 (-4.15%)
Updated
Jun 13 closing price
Capitalization
664.29M
64 days until earnings call
XBIO
Price
$3.01
Change
-$0.23 (-7.10%)
Updated
Jun 13 closing price
Capitalization
4.65M
Interact to see
Advertisement

TSHA vs XBIO

Header iconTSHA vs XBIO Comparison
Open Charts TSHA vs XBIOBanner chart's image
Taysha Gene Therapies
Price$2.54
Change-$0.11 (-4.15%)
Volume$2.46M
Capitalization664.29M
Xenetic Biosciences
Price$3.01
Change-$0.23 (-7.10%)
Volume$7.84K
Capitalization4.65M
TSHA vs XBIO Comparison Chart
Loading...
TSHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TSHA vs. XBIO commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TSHA is a StrongBuy and XBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (TSHA: $2.54 vs. XBIO: $3.01)
Brand notoriety: TSHA and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: TSHA: 62% vs. XBIO: 89%
Market capitalization -- TSHA: $664.29M vs. XBIO: $4.65M
TSHA [@Biotechnology] is valued at $664.29M. XBIO’s [@Biotechnology] market capitalization is $4.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TSHA’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • TSHA’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both TSHA and XBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TSHA’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 0 bullish TA indicator(s).

  • TSHA’s TA Score: 4 bullish, 4 bearish.
  • XBIO’s TA Score: 0 bullish, 2 bearish.
According to our system of comparison, TSHA is a better buy in the short-term than XBIO.

Price Growth

TSHA (@Biotechnology) experienced а -10.56% price change this week, while XBIO (@Biotechnology) price change was +1.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

TSHA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TSHA($664M) has a higher market cap than XBIO($4.65M). TSHA YTD gains are higher at: 46.821 vs. XBIO (-24.489). XBIO has higher annual earnings (EBITDA): -3.88M vs. TSHA (-85.47M). TSHA has more cash in the bank: 117M vs. XBIO (5.16M). XBIO has less debt than TSHA: XBIO (153K) vs TSHA (61.4M). TSHA has higher revenues than XBIO: TSHA (7.22M) vs XBIO (2.58M).
TSHAXBIOTSHA / XBIO
Capitalization664M4.65M14,292%
EBITDA-85.47M-3.88M2,204%
Gain YTD46.821-24.489-191%
P/E Ratio2.70N/A-
Revenue7.22M2.58M280%
Total Cash117M5.16M2,266%
Total Debt61.4M153K40,131%
FUNDAMENTALS RATINGS
XBIO: Fundamental Ratings
XBIO
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
81
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
TSHAXBIO
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
N/A
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend about 1 month ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend about 1 month ago
83%
Advances
ODDS (%)
Bullish Trend 27 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend about 1 month ago
87%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
TSHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CETX1.030.01
+0.98%
Cemtrex In
IRMD58.17-1.39
-2.33%
iRadimed Corp
LTM38.05-1.41
-3.57%
LATAM Airlines Group S.A.
CWK10.41-0.39
-3.61%
Cushman & Wakefield plc
ATOS0.83-0.03
-3.74%
Atossa Therapeutics

TSHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with SLDB. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSHA
1D Price
Change %
TSHA100%
-4.15%
SLDB - TSHA
42%
Loosely correlated
-1.53%
TRDA - TSHA
41%
Loosely correlated
-3.31%
LRMR - TSHA
39%
Loosely correlated
-1.03%
COGT - TSHA
38%
Loosely correlated
-1.94%
DNTH - TSHA
38%
Loosely correlated
-5.08%
More

XBIO and

Correlation & Price change

A.I.dvisor tells us that XBIO and ELEV have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBIO and ELEV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-7.01%
ELEV - XBIO
28%
Poorly correlated
+0.39%
CGEN - XBIO
24%
Poorly correlated
-1.20%
ABUS - XBIO
24%
Poorly correlated
-1.40%
GOSS - XBIO
23%
Poorly correlated
-2.36%
TSHA - XBIO
23%
Poorly correlated
-4.15%
More